Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of AN2898 and AN2728 Topical Ointments to Treat Mild-to-Moderate Atopic Dermatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of atopic dermatitis that has been clinically stable for ≥1 month~* Total body surface area (BSA) of atopic dermatitis involvement ≤35%, excluding involvement of the face, scalp, and groin~* Presence of two (2) comparable target lesions~* Willing and able to apply study medications as directed, comply with study instructions, and commit to attending all visits~* Females of childbearing potential must use at least one highly effective method of birth control. Males with partners of childbearing potential should inform them of their participation in this clinical study and use highly effective methods of birth control during the study.~Exclusion Criteria:~* Concurrent or recent use of certain topical or systemic medications or phototherapy without a sufficient washout period~* Active or potentially recurrent dermatologic condition other than atopic dermatitis in the target lesion area that may confound evaluation~* Significant confounding conditions as assessed by study doctor~* History or evidence of allergies requiring acute or chronic treatment (except seasonal allergic rhinitis)~* Participated in any other trial of an investigational drug or device within 30 days or participation in a research study concurrent with this study~* Pregnancy or lactation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- AN2898 ointment, 1%, vs. ointment vehicle (Type: EXPERIMENTAL): AN2898 ointment applied twice daily for 6 weeks to one target lesion, and AN2898 ointment vehicle applied twice daily for 6 weeks to a second target lesion.~Treatments will be randomly assigned to target lesions A and B.
- AN2728 ointment, 2%, vs. ointment vehicle (Type: EXPERIMENTAL): AN2728 ointment applied twice daily for 6 weeks to one target lesion, and AN2728 ointment vehicle applied twice daily for 6 weeks to a second target lesion.~Treatments will be randomly assigned to target lesions A and B.

Based on this trial design, predict the completion outcome and termination type (if applicable).